Loading…
Legislative Progress
Introduced
March 15, 2023
Latest Action
March 15, 2023
Primary Sponsor
Robert P. Casey, Jr.Democratic(PA)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 5,649 other S bills in the 118th — cohort avg 33d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (2)
2024 · second_quarter · Health Issues
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Read twice and referred to the Committee on Finance.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2024 · first_quarter · Health Issues
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options. Monitoring of regulatory proposals impacting inclusion of routine non-pediatric dental services as Essential Health Benefits (EHBs)
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2023 · fourth_quarter · Health Issues
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023 S.842 - Medicare and Medicaid Dental, Vision, and Hearing Benefit Act of 2023; H.R. 6284 Improving Measurements for Loneliness and Isolation Act; H.R. 4150/S.1954 Improving Whole Health for Veterans with Chronic Conditions Act; H.R. 4146 /S.2012 Medicare Dental Benefit Act of 2023 S.3393 SUPPORT for Patients and Communities Reauthorization Act, specifically provisions related to non-opioid alternatives to acute and chronic pain management; and General review of legislation and amendments focusing on non-addictive, non-opioid pain management medications, with a focus on over-the-counter (OTC) options.
Client expense: $140,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · third_quarter · Health Issues
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Defense Production Act (DPA) issues, specifically on manufacturing impacts on over-the-counter medications. S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023
Client expense: $190,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · second_quarter · Health Issues
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; General review and monitoring of processes impacting over-the-counter switches, including Nonprescription Drug Product with an Additional Condition for Nonprescription Use (ACNU) rulemaking process Monitor and engage on legislative and administrative action related to phenylephrine and pseudoephedrine regulation. General monitoring of issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA Defense Production Act (DPA) issues, specifically on manufacturing impacts on over-the-counter medications. S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders. H.R. 831 Medicare Medically Necessary Dental Care Act of 2023
Client expense: $180,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2023 · first_quarter · Health Issues
General monitoring of legislative and administrative action related to health care policy; General monitoring of legislative and administrative action related to womens health issues; General monitoring of legislative and administrative action related to over-the-counter consumer healthcare products; General monitoring of legislative and administrative action related to dietary supplements, multivitamin, and hunger issues; General monitoring of legislative and administrative action related to servicing of medical device equipment; General monitoring of legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP); General monitoring of legislative and administrative action related to FDA monograph reform and user fees; General monitoring of legislative and administrative action related to the switch of prescription medications to over-the-counter medications; Review of issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); Review of coverage for medically necessary services in Medicare and Medicare Advantage, including dental coverage, to address underlying conditions in advance of major surgery; S. 818 Maximizing Opioid Recovery Emergency Savings Act, in particular, provisions related to drugs and biologicals; Review of legislation impacting the Dietary Supplement Health and Education Act of 1994, in particular, provisions related to Mandatory Product Listing (MPL); and S. 923, Better Mental Health Care for Americans Act, specifically provisions related to substance use disorders.
Client expense: $140,000 · Firm income: Not reported
No bill number. Discussed equitable funding for community health care, nursing home safety, and health and nutrition for Puerto Rico and other Territories. No bill number. Discussed over-the-counter hearing aid regulations. No bill number. Discussed Medicare and Medicare Advantage. No bill number. Discussed individual market commercial health insurance. No bill number. Discussed health care workforce training and shortages. No bill number. Discussed the Affordable Care Act Proposed Notice of Benefit and Payment Parameters for 2024. H.R. 382, the Pandemic is Over Act. S.818, Maximizing Opioid Recovery Emergency (MORE) Savings Act. No bill number. Discussed home and community-based services, health care workforce, family caregiving, direct care workforce, and nurses. No bill number. Discussed prescription drug policy, health care transparency, competition, and affordability. No bill number. Discussed rare diseases.
Client expense: $3,850,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Consumer Product Safety Commission (CPSC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office